[blog & news]
September 17, 2026
Blog
Beacon-2: Completing the reward function for chemical optimization in drug discovery
Dose is the primary reward function of pre-clinical discovery, and we believe that making it computable via Beacon-2 is a step change for AI in drug discovery. Now, instead of optimizing individual properties in isolation, agentic systems can drive the drug discovery process itself.
September 14, 2026
News
Inductive Bio launches Indy, an AI chemistry assistant, to double the capacity of every medicinal chemist
Indy is the world’s first medicinal chemistry agent. Indy outperforms Claude Opus 5 and GPT-5.6 Sol in head-to-head benchmarks that include QC’ing new assay data, analyzing SAR, and the design/triage of analogs.
September 14, 2026
Blog
Meet Indy: an AI chemistry assistant designed by medicinal chemists to do medicinal chemistry
Indy, our medicinal chemistry assistant, supports drug discovery programs in improving the rigor of day-to-day analyses and decisions, by QC-ing assay data and monitoring the synthesis queue, to launching FEP, projecting human dose, and making meeting-ready SAR and synthesis slides.
June 30, 2026
News
Inductive Bio joins Anthropic’s Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through Claude
Inductive’s global ADMET prediction models are now available as a connector for Claude, enabling any drug discovery scientist working with Claude to access state-of-the-art predictive models directly in their existing workflow.
May 26, 2026
News
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification
December 8, 2025
News
Inductive Bio Announces an up to $21M Award to Develop AI Drug Toxicity Models that Improve Drug Safety Assessment with Leading Academic and Biopharmaceutical Organizations
Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing
August 20, 2025
News
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry
This new partnership will streamline drug discovery with AI, faster ADME profiling, and automated compound management, helping scientists design better treatments with fewer resources.
May 8, 2025
News
Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
Funding will accelerate company’s work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapies
March 14, 2025
News
Inductive Bio to Present at ACS Spring 2025 on the Future of AI in Drug Discovery
The rapid rise of AI in drug discovery brings both unprecedented opportunities and complex challenges. From accelerating the development of better therapies to navigating the proliferation of tools and technologies, the path forward requires clarity, precision, and innovation. For small biotech companies, this moment also raises a critical question: how can we stay competitive with limited resources?
September 29, 2024
News
Inductive Bio Announces Publication of Successful Drug Optimization Collaboration with Nested Therapeutics
Inductive Bio, a leader in leveraging machine learning (ML) to accelerate compound optimization for small molecule drug discovery, announces the publication of the approach and findings from their recent collaboration with Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers.
August 9, 2024
News
Inductive Bio to Host Panel on AI and ML in Drug Discovery at ACS Fall 2024
As artificial intelligence and machine learning continue to reshape the landscape of drug discovery, this panel will tackle one of the field’s most pressing questions: how do we separate real innovation from overpromised potential?
August 1, 2024
Blog
Are local or global models better? Why not both?
A long-standing debate in cheminformatics is whether global property-prediction models perform better or worse than local QSAR models. We describe a result from our publication with Nested Therapeutics in which we show that the best of both worlds is to train a model on global data and then fine-tune it on local data.
June 7, 2024
Blog
Approaching AlphaFold 3 docking accuracy in 100 lines of code
AlphaFold 3 (AF3) is an exciting leap forward in our ability to predict the structure and properties of biomolecular systems. We explore how AF3 small-molecule docking compares to existing techniques and find that the story is more nuanced than headlines suggest. We conclude with thoughts on where AF3 may ultimately be most useful.
December 13, 2023
News
Inductive Bio Emerges from Stealth, Unveiling an ML Platform to Accelerate Compound Optimization in Drug Discovery
Inductive Bio emerged with $4.3M in a seed funding round co-led by a16z Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others. Inductive's team has deep expertise building innovative ML products and bringing drugs into the clinic.
November 20, 2023
Blog
Get with the program: building ADME datasets that drive impact
Research advances often don't translate to practical impact. In ML for small molecule drug discovery, this is at least partly because benchmark datasets don't capture important components of drug programs. We show how this can happen in ADME prediction and provide a path forward for building more realistic benchmarks from existing public data.